Prospective phase II [69,70,71] and randomized phase III trials [7,8,65] led to the approval of cetuximab, a chimeric anti-EGFR-antibody for treating SCCHN both in the primary, curative setting, combined with RT and in the R/M setting combined with chemotherapy. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.